Baker Bros. Advisors Adds $18M in Generate Biomedicines, Inc. ($GENB)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors acquired a new position in Generate Biomedicines, Inc. ($GENB), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,423,602 shares of Generate Biomedicines, Inc.. Baker Bros. Advisors's holdings in Generate Biomedicines, Inc. were worth $18.17 million as of its most recent filing.
Generate Biomedicines, Inc. Stock Down 16.8%
Shares of Generate Biomedicines, Inc. ($GENB) traded around $12.76 on Saturday, down 16.8% for the day.
Generate Biomedicines, Inc. Earnings
Analysts Set New Price Targets
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Get Generate Biomedicines, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GENB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.